
Renal Biomarker
Description
Renal Biomarker
Global Renal Biomarkers Market to Reach $1.5 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Renal Biomarkers estimated at US$937.6 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027. Functional Biomarkers, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$810.1 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Up-Regulated Proteins segment is readjusted to a revised 6.3% CAGR for the next 7-year period.
The U.S. Market is Estimated at $271.2 Million, While China is Forecast to Grow at 6% CAGR
The Renal Biomarkers market in the U.S. is estimated at US$271.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$254.5 Million by the year 2027 trailing a CAGR of 5.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
Other Biomarkers Segment to Record 4.9% CAGR
In the global Other Biomarkers segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$87.3 Million in the year 2020 will reach a projected size of US$122.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Global Renal Biomarkers Market to Reach $1.5 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Renal Biomarkers estimated at US$937.6 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027. Functional Biomarkers, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$810.1 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Up-Regulated Proteins segment is readjusted to a revised 6.3% CAGR for the next 7-year period.
The U.S. Market is Estimated at $271.2 Million, While China is Forecast to Grow at 6% CAGR
The Renal Biomarkers market in the U.S. is estimated at US$271.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$254.5 Million by the year 2027 trailing a CAGR of 5.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
Other Biomarkers Segment to Record 4.9% CAGR
In the global Other Biomarkers segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$87.3 Million in the year 2020 will reach a projected size of US$122.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
Select Competitors (Total 44 Featured) -
- Abbott Molecular, Inc.
- Astute Medical, Inc.
- Beckman Coulter, Inc.
- BioPorto Diagnostics A/S
- Randox Laboratories Ltd.
- Thermo Fisher Scientific, Inc.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
193 Pages
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Renal Biomarker – Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Renal Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 2: World Historic Review for Renal Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 3: World 15-Year Perspective for Renal Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
- TABLE 4: World Recent Past, Current & Future Analysis for Functional Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 5: World Historic Review for Functional Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 6: World 15-Year Perspective for Functional Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 7: World Recent Past, Current & Future Analysis for Up-Regulated Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 8: World Historic Review for Up-Regulated Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 9: World 15-Year Perspective for Up-Regulated Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 10: World Recent Past, Current & Future Analysis for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 11: World Historic Review for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 12: World 15-Year Perspective for Other Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 13: World Recent Past, Current & Future Analysis for Enzyme Linked Immunosorbent Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 14: World Historic Review for Enzyme Linked Immunosorbent Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 15: World 15-Year Perspective for Enzyme Linked Immunosorbent Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 16: World Recent Past, Current & Future Analysis for Particle-Enhanced Turbidimetric Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 17: World Historic Review for Particle-Enhanced Turbidimetric Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 18: World 15-Year Perspective for Particle-Enhanced Turbidimetric Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 19: World Recent Past, Current & Future Analysis for Colorimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 20: World Historic Review for Colorimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 21: World 15-Year Perspective for Colorimetric Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 22: World Recent Past, Current & Future Analysis for Chemiluminescent Enzyme Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 23: World Historic Review for Chemiluminescent Enzyme Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 24: World 15-Year Perspective for Chemiluminescent Enzyme Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 25: World Recent Past, Current & Future Analysis for Liquid Chromatography-Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 26: World Historic Review for Liquid Chromatography-Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 27: World 15-Year Perspective for Liquid Chromatography-Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 28: World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 29: World Historic Review for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 30: World 15-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 31: World Recent Past, Current & Future Analysis for Outpatient Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 32: World Historic Review for Outpatient Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 33: World 15-Year Perspective for Outpatient Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 34: World Recent Past, Current & Future Analysis for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 35: World Historic Review for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 36: World 15-Year Perspective for Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 37: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 38: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 39: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 40: World Renal Biomarker Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027
- III. MARKET ANALYSIS
- UNITED STATES
- Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
- TABLE 41: USA Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 42: USA Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 43: USA 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 44: USA Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 45: USA Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 46: USA 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 47: USA Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 48: USA Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 49: USA 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- CANADA
- TABLE 50: Canada Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 51: Canada Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 52: Canada 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 53: Canada Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 54: Canada Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 55: Canada 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 56: Canada Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 57: Canada Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 58: Canada 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- JAPAN
- Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
- TABLE 59: Japan Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 60: Japan Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 61: Japan 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 62: Japan Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 63: Japan Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 64: Japan 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 65: Japan Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 66: Japan Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 67: Japan 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- CHINA
- Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
- TABLE 68: China Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 69: China Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 70: China 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 71: China Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 72: China Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 73: China 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 74: China Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 75: China Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 76: China 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- EUROPE
- Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
- TABLE 77: Europe Recent Past, Current & Future Analysis for Renal Biomarker by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 78: Europe Historic Review for Renal Biomarker by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 79: Europe 15-Year Perspective for Renal Biomarker by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
- TABLE 80: Europe Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 81: Europe Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 82: Europe 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 83: Europe Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 84: Europe Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 85: Europe 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 86: Europe Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 87: Europe Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 88: Europe 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- FRANCE
- Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
- TABLE 89: France Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 90: France Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 91: France 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 92: France Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 93: France Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 94: France 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 95: France Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 96: France Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 97: France 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- GERMANY
- Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
- TABLE 98: Germany Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 99: Germany Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 100: Germany 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 101: Germany Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 102: Germany Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 103: Germany 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 104: Germany Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 105: Germany Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 106: Germany 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- ITALY
- TABLE 107: Italy Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 108: Italy Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 109: Italy 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 110: Italy Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 111: Italy Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 112: Italy 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 113: Italy Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 114: Italy Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 115: Italy 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- UNITED KINGDOM
- Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
- TABLE 116: UK Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 117: UK Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 118: UK 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 119: UK Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 120: UK Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 121: UK 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 122: UK Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 123: UK Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 124: UK 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- REST OF EUROPE
- TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 126: Rest of Europe Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 127: Rest of Europe 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 129: Rest of Europe Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 130: Rest of Europe 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 132: Rest of Europe Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 133: Rest of Europe 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- ASIA-PACIFIC
- Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
- TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 135: Asia-Pacific Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 136: Asia-Pacific 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 138: Asia-Pacific Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 139: Asia-Pacific 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 141: Asia-Pacific Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 142: Asia-Pacific 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- REST OF WORLD
- TABLE 143: Rest of World Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 144: Rest of World Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 145: Rest of World 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
- TABLE 146: Rest of World Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 147: Rest of World Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 148: Rest of World 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
- TABLE 149: Rest of World Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 150: Rest of World Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 151: Rest of World 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
- IV. COMPETITION
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.